Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Survival Rates of Patients With Breast Cancer in Countries in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis; [Taux De Survie Des Patients Atteints De Cancer Du Sein Dans Les Pays De La Region De La Mediterranee Orientale: Analyse Systematique Et Meta-Analyse] Publisher Pubmed



Maajani K1 ; Khodadost M2, 3 ; Fattahi A4 ; Pirouzi A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Neurosurgery, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran

Source: Eastern Mediterranean Health Journal Published:2020


Abstract

Background: Breast cancer is the fourth leading cause of death and disability in the Eastern Mediterranean Region (EMR); although the incidence is lower than in the developed regions, there has been an increasing trend in recent decades. Aims: Our aim was to calculate the pooled survival rate of patients with breast cancer in the EMR. Methods: We searched electronic databases from 1946 to 19 January 2018, without language restrictions. We used a random effect model to estimate pooled 1-, 3-, 5-and 10-year survival rates for patients with breast cancer. Chi-squared and I2 index were used to assess between-study heterogeneity. Subgroup analysis and meta-regression were used to investigate the potential source of heterogeneity. Results: We found 80 articles eligible for inclusion in our review. The pooled 1-, 3-, 5-and 10-year survival rates in women with breast cancer in the EMR were 0.95, 0.80, 0.71, and 0.56, respectively. The I2 index indicated considerable between-study heterogeneity (all I2 > 50%). The 5-year survival rate in the male subgroup was 0.63. The 5-year survival rate of women with breast cancer in age groups ≤ 39, 40–64, and 65+ years were 0.74, 0.76 and 0.58, respectively. There was a statistically significant association between the Human Development Index (β = 9, P = 0.01) and decade of study (β = 8.2, P = 0.04) and 5-year survival rate. Conclusions: The survival rate of women with breast cancer in those countries in the EMR which have better health care systems improved in the past decade; women aged 40–64 years had the best survival rate. © World Health Organization (WHO) 2020.